Clinical Report: Autologous Serum Made Simple

Overview

Autologous serum tears (AST) are emerging as a potential first-line treatment for dry eye disease (DED), particularly in cases of neural dysfunction. Recent clinical trials demonstrate AST's efficacy in improving both symptoms and objective signs of DED compared to artificial tears.

Background

Dry eye disease is a prevalent condition affecting hundreds of millions globally, leading to significant patient discomfort and health implications. The Tear Film & Ocular Surface Society's latest guidelines emphasize a personalized treatment approach, positioning AST as a viable option for patients with severe symptoms or specific ocular surface needs. The transition from a stepped treatment approach to a more individualized strategy highlights the importance of innovative therapies like AST in managing DED.

Data Highlights

Key Findings

• AST contains growth factors and components similar to natural tears, promoting epithelial growth.
• A randomized trial showed AST significantly improved OSDI and VAS scores compared to artificial tears.
• AST has a favorable safety profile, with only mild irritation reported in a minority of patients.
• The average cost for AST is approximately $130 per month, with some insurance providers recognizing it as medically necessary.
• Centralized production of AST addresses previous concerns regarding sterility and consistency.

Clinical Implications

Healthcare providers should consider AST as a first-line treatment option for patients with severe dry eye disease, particularly those with neural dysfunction. The rapid delivery and individualized preparation of AST can enhance patient adherence and satisfaction.

Conclusion

The adoption of autologous serum tears represents a significant advancement in the management of dry eye disease, aligning with the latest clinical guidelines that advocate for personalized treatment approaches.

References

1. Jones L, Craig JP, Markoulli M, et al., Am J Ophthalmol, 2026 -- TFOS DEWS III Management and Therapy Report
2. Venkateswaran N, Ophthalmology Management, 2024 -- Serum Tears in the Treatment of Dry Eye and Ocular Surface Disease
3. Blood Cancer Journal — Enhanced Detection of Blood-Based M-Protein in sCR Patients with Multiple Myeloma
4. Open Forum Infectious Diseases — Identification of Anti-IFNγ Autoantibodies Using Dried Blood Spot Samples
5. Contact Lens Spectrum — Dry Eye Dx and Tx
6. TFOS DEWS III report
7. Dry Eye Syndrome Preferred Practice Pattern®
8. Autologous serum eye drops for patients with dry eye disease: a systematic review and meta-analysis of randomized controlled trials - PMC